BiotechTube

V114 + Prevnar 13®

Phase 3Completed
0 views this week 0 watching⚡ Active
Interest: 40/100
40
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Pneumococcal Infections

Conditions

Pneumococcal Infections

Trial Timeline

Jun 25, 2019 → Dec 9, 2020

NCT ID
NCT03885934

About V114 + Prevnar 13®

V114 + Prevnar 13® is a phase 3 stage product being developed by Merck for Pneumococcal Infections. The current trial status is completed. This product is registered under clinical trial identifier NCT03885934. Target conditions include Pneumococcal Infections.

What happened to similar drugs?

15 of 20 similar drugs in Pneumococcal Infections were approved

Approved (15) Terminated (1) Active (5)
✅PNEUMOVAX™ 23MerckApproved
✅Simultaneous administration of Pneumovax NP® and Fluvic HA syringe® + Sequential administration of Pneumovax NP® and Fluvic HA syringe®MerckApproved
✅21-valent pneumococcal conjugate vaccineMerckApproved
✅ProDiax-23 (PPSV23)MerckApproved
✅13-valent pneumococcal conjugate vaccine + 13-valent pneumococcal conjugate vaccinePfizerApproved
✅pneumococcus conjugate vaccine 7 valent to reduce carriagePfizerApproved
✅pneumococcus conjugate vaccinePfizerApproved

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (2)

NCT IDPhaseStatus
NCT03885934Phase 3Completed
NCT03950622Phase 3Completed

Competing Products

20 competing products in Pneumococcal Infections

See all competitors
ProductCompanyStageHype Score
V116 + PPSV23MerckPhase 3
40
V114 + QIV + Matching Placebo for V114MerckPhase 3
40
V114 + Prevnar 13™ + PNEUMOVAX™23MerckPhase 3
40
V114 Lot 1 + V114 Lot 2 + Prevnar 13™MerckPhase 2
35
PNEUMOVAX™ 23MerckApproved
43
Pneumococcal Vaccine, Polyvalent (23-valent)MerckPhase 3
40
V114 + Prevnar 13™ + PNEUMOVAX™23MerckPhase 3
40
V114 Medium Dose + V114 High Dose + V114 Medium Dose with Alternative Carrier Protein + V114 High Dose with Alternative Carrier Protein + Prevnar 13™MerckPhase 1/2
32
V116 + PPSV23MerckPhase 3
40
V114MerckPhase 3
40
Prevnar 13™ + V114 + RotaTeq™ + Pentacel™ + RECOMBIVAX HB™ + HIBERIX™ + M-M-R™ II + VARIVAX™MerckPhase 3
40
V114 + Prevnar 13®MerckPhase 3
40
Pneumococcal Conjugate Vaccine (V114) + PNEUMOVAX® 23 + PREVNAR 13®MerckPhase 2
35
V114-A + V114-B + Prevnar 13®MerckPhase 2
35
V116 + Pneumovax™23MerckPhase 1/2
32
V114 + Prevnar 13™MerckPhase 3
40
V114 + Prevnar 13™MerckPhase 2
35
Simultaneous administration of Pneumovax NP® and Fluvic HA syringe® + Sequential administration of Pneumovax NP® and Fluvic HA syringe®MerckApproved
43
21-valent pneumococcal conjugate vaccineMerckApproved
50
V116 + PPSV23MerckPhase 3
40